KM Biologics’ COVID-19 Vaccine Approval Likely to Delay into FY2023

KM Biologics’ inactivated COVID-19 vaccine KD-414, which the company expected would obtain Japanese approval in FY2022, is now not likely to be approved until sometime in FY2023, with the use of the emergency approval pathway seen difficult. Meiji Holdings, the...read more